Technology
Health
Biotechnology

Radius Health

$22.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.25%) As of 10:50 AM EDT today
+$0.05 (0.25%) Today

Why Robinhood?

You can buy or sell Radius Health and other stocks, options, ETFs, and crypto commission-free!

About RDUS

Radius Health, Inc. Common Stock, also called Radius Health, is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. Read More The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

Employees
398
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
1.03B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
360.90K
High Today
$22.77
Low Today
$22.41
Open Price
$22.48
Volume
58.03K
52 Week High
$28.84
52 Week Low
$12.81

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical
2014 IPO

RDUS Earnings

-$1.59
-$1.28
-$0.97
-$0.66
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.